Streamlining Pediatric Oncology GLP-1 Prior Auth Workflows

The Unique Intersection of Pediatric Oncology and GLP-1 PA

While the primary focus in pediatric oncology is life-saving cancer treatment, childhood cancer patients often present with complex comorbidities or develop conditions like steroid-induced hyperglycemia or obesity, necessitating GLP-1 receptor agonist therapy. These prescriptions, including for drugs like Saxenda and Zepbound, trigger high-volume prior authorization requirements, frequently involving step therapy, specific BMI/A1C documentation, and detailed weight loss tracking. This adds significant administrative load to clinics already managing PAs for chemotherapy regimens and advanced therapies.

Navigating Payer Policies for GLP-1s in Pediatric Populations

Payer policies for GLP-1 receptor agonists vary widely, particularly concerning indications for type 2 diabetes versus obesity. For pediatric oncology patients, demonstrating medical necessity often requires precise documentation from the EMR, including growth charts, relevant lab values, and comorbidity status. Klivira's policy engine maintains up-to-date per-payer obesity benefit status and brand-specific PA criteria, enabling accurate indication classification and routing for drugs such as Ozempic and Wegovy, critical for reducing denials and accelerating access.

Klivira's Automated GLP-1 Prior Authorization Workflow for Pediatric Oncology

• **Indication Classification:** Klivira identifies type 2 diabetes versus obesity indication directly from EMR diagnosis and clinical context, relevant for pediatric patients with metabolic comorbidities.
• **Per-Payer Obesity-Coverage Routing:** Our policy engine maintains current per-payer obesity benefit status, routing GLP-1 PAs (e.g., for Mounjaro, Zepbound) based on coverage, restrictions, or exclusions.
• **Step Therapy Documentation Automation:** Automatically pulls metformin trial history, BMI documentation, and comorbidity status from FHIR-enabled EMRs, adapting to pediatric growth standards where applicable.
• **Brand-Specific Routing:** Applies distinct PA criteria for different GLP-1 products, ensuring compliance with specific requirements for Ozempic, Wegovy, and other medications.
• **Specialty Pharmacy Fulfillment:** Post-approval, Klivira facilitates routing to specialty pharmacies, a common requirement for many GLP-1 products prescribed in pediatric settings.
• **Patient Financial Counseling Integration:** When obesity indications are denied, Klivira surfaces manufacturer copay programs and alternative coverage paths, supporting families through complex financial landscapes.

Seamless Integration and Clinical Context

Klivira integrates with leading EMRs via SMART on FHIR, enabling bidirectional data exchange for GLP-1 prior authorizations. This allows pediatric oncology teams to initiate and track PAs directly within their clinical workflows, pulling necessary documentation like ADA Standards of Care criteria for T2D management or relevant NCCN/ASCO guidelines for associated comorbidities. Our platform also supports standard X12 278 transactions and connects to payer portals, ensuring comprehensive connectivity for all GLP-1 PA submissions.

Reducing Administrative Burden and Improving Patient Outcomes

By automating the complex and high-volume GLP-1 prior authorization process, Klivira frees up pediatric oncology prior authorization coordinators to focus on critical, high-acuity PAs for cancer treatments. This reduction in manual effort minimizes delays in medication access for pediatric patients requiring GLP-1s, enhancing adherence to treatment plans, and ultimately supporting better overall health outcomes alongside their primary oncology care. The CAQH Index highlights the significant administrative burden of pharmacy ePA volumes, a burden Klivira directly addresses.